Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Argenica Therapeutics Ltd ( (AU:AGN) ) has issued an update.
Argenica Therapeutics has announced the resignation of Non-Executive Chair and Director Dianne Angus, effective at the end of December, after two years on the board during which she helped steer the company through early-stage clinical development, including a successful Phase 2 trial in acute ischaemic stroke and the strategic expansion of its therapeutic pipeline. The board credited Angus with embedding robust governance, risk management and compliance frameworks suited to a clinical-stage biotech and said it has begun searching for a new chair with strong global business development and strategic partnering experience to support Argenica’s planned international growth, signalling an intensifying focus on commercialisation and overseas expansion as the company advances its neuroprotective candidates.
The most recent analyst rating on (AU:AGN) stock is a Buy with a A$0.63 price target. To see the full list of analyst forecasts on Argenica Therapeutics Ltd stock, see the AU:AGN Stock Forecast page.
More about Argenica Therapeutics Ltd
Argenica Therapeutics Limited is a clinical-stage biotechnology company focused on developing novel neuroprotective therapeutics to reduce brain tissue death following stroke, brain injury and neurodegenerative diseases, with lead peptide candidate ARG-007 having completed Phase 1 safety studies in healthy volunteers and a Phase 2 trial in acute ischaemic stroke patients, alongside ongoing preclinical work in other neurological indications.
Average Trading Volume: 220,625
Technical Sentiment Signal: Sell
Current Market Cap: A$34.68M
See more insights into AGN stock on TipRanks’ Stock Analysis page.